Pioneering Flemish personalized medicine partnership
with support of
Persomed partners will
jointly develop an innovative
colon cancer vaccine
"More personalized therapies potentially
enable to put a stop to colon cancer"
- Bart Van Acker, CEO QbD
"With Persomed, we have all the
required resources to go full force"
- Jan Schrooten, CEO Antleron